Florian Simon

16PUBLICATIONS
60CO-AUTHORS
Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCellular immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 12, 2026
Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Sep 04, 2025
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Jan 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Moritz Fürstenau, Sandra Robrecht, Christof Schneider

|Dec 10, 2024
Surrogate endpoints in mature B-cell neoplasms - meaningful or misleading?

Florian Simon, Othman Al-Sawaf, John F Seymour

Pageof 3

Frequent Collaborators

10 joint publications

Moritz Fürstenau

9 joint publications

Michael J Hallek

7 joint publications

Othman Al-Sawaf

6 joint publications

Carsten Utoft Niemann